Benitec Biopharma Inc.

NASDAQ:BNTC

Biotechnology

Healthcare
$8.15 +3.05%

+$0.36 today

Market cap
$284.35M
Beta
0.28
P/E (TTM)
-12.3
EPS (TTM)
-$0.99
52W Low $9.85High $16.76

Volume 0.18M

Average 0.11M

Returns on capital

Benitec Biopharma Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-39.0%

avg -976.0%

ROIC

-42.6%

avg -296.8%

ROA

-38.1%

avg -103.2%

Analysis

ROA is currently the strongest return metric at -38.1% versus its period average of -103.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Jerel A. Banks

Executive Chairman & Chief Executive OfficerAUD 1.26M51450.00K1.71%

Sophie Mukadam

Chief Operating OfficerAUD 870.44K45500.00K1.90%

Megan Joan Boston

CFO & SecretaryAUD 833.04K54——

Michael Graham

Head of Discovery & Founding ScientistAUD 135.96K———

Claudia Kloth

Senior Vice President of Manufacturing————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 18, 2025.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

12

$2.44M

Sells

0

$0.00

Net Transaction Value

+$2.44M

Net buying

Most Active

SUVRETTA CAPITAL MANAGEMENT, LLC

12 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Dec 29, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$155.7K
Dec 29, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$884.4K
Dec 26, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$187.6K
Dec 26, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$33K
Dec 23, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$95.1K
Dec 23, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$547.4K
Dec 22, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$34.9K
Dec 22, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$201.1K
Dec 19, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$160.1K
Dec 19, 25

SUVRETTA CAPITAL MANAGEMENT, LLC

Indirect

Buy$27.9K

1–10 of 12

Summary

Insiders reported 12 buys worth $2.44M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $2.44M. SUVRETTA CAPITAL MANAGEMENT, LLC was the most active insider with 12 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
N/A1 analysts
Net IncomeN/AN/AN/A
N/A1 analysts
EBITN/AN/AN/A
N/A1 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Benitec Biopharma Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BNTC's management, answered from reported figures.

Who manages BNTC?

Benitec Biopharma Inc. (BNTC) lists 5 active executives. The top listed executive is Claudia Kloth, Senior Vice President of Manufacturing.

Are BNTC insiders buying or selling?

Recent insider activity shows net buying of $99.87M.